Understanding the Adverse Events of PARP Inhibitors

There are some adverse events that are common to all PARP inhibitors, and others that are specific to each drug.

There are three adverse events (AEs) that are common to all the PARP inhibitors used to treat ovarian cancer: fatigue, anemia, and nausea, explained Bobbie J. Rimel, MD, an assistant professor of obstetrics and gynecology at Cedars-Sinai.

However, there are also AEs that tend to be more common for certain agents. For example, niraparib (Zejula) is more likely to cause high blood pressure; rucaparib (Rubraca) is more likely to affect kidney function; and olaparib (Lynparza) is more likely to cause gastrointestinal issues.

Related Videos
Karyn Goodman
Reanne Booker on Factors to Consider When Discussing Palliative Radiation
Related Content
© 2023 MJH Life Sciences

All rights reserved.